TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status |
| |
| Authors: | Sumit Agarwal,Michael Behring,Hyung‐ Gyoon Kim,Darshan S. Chandrashekar,Balabhadrapatruni V. S. K. Chakravarthi,Nirzari Gupta,Prachi Bajpai,Amr Elkholy,Sameer Al Diffalha,Pran K. Datta,Martin J. Heslin,Sooryanarayana Varambally,Upender Manne |
| |
| Affiliation: | 1. Department of Pathology, University of Alabama at Birmingham, AL, USA ; 2. Department of Chemistry, University of Alabama at Birmingham, AL, USA ; 3. Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, AL, USA ; 4. Department of Surgery, University of Alabama at Birmingham, AL, USA ; 5. O''Neal Comprehensive Cancer Center, University of Alabama at Birmingham, AL, USA |
| |
| Abstract: | Overexpression of TRIP13, a member of the AAA‐ATPase family, is linked with various cancers, but its role in metastasis is unknown in colorectal cancer (CRC). In the current study, we investigated the role TRIP13 in experimental metastasis and its involvement in regulation of WNT/β‐catenin and EGFR signaling pathways. Evaluation of formalin‐fixed paraffin‐embedded (FFPE) and frozen tissues of adenomas and CRCs, along with their corresponding normal samples, showed that TRIP13 was gradually increased in its phenotypic expression from adenoma to carcinoma and that its overexpression in CRCs was independent of patient''s gender, age, race/ethnicity, pathologic stage, and p53 and microsatellite instability (MSI) status. Moreover, liver metastases of CRCs showed TRIP13 overexpression as compared to matched adjacent liver tissues, indicating the biological relevance of TRIP13 in CRC progression and metastasis. TRIP13 knockdown impeded colony formation, invasion, motility, and spheroid‐forming capacity of CRC cells irrespective of their p53 and MSI status. Furthermore, xenograft studies demonstrated high expression of TRIP13 contributed to tumor growth and metastasis. Depletion of TRIP13 in CRC cells decreased metastasis and it was independent of the p53 and MSI status. Furthermore, TRIP13 interacted with a tyrosine kinase, FGFR4; this interaction could be essential for activation of the EGFR‐AKT pathway. In addition, we demonstrated the involvement of TRIP13 in the Wnt signaling pathway and in the epithelial–mesenchymal transition. Cell‐based assays revealed that miR‐192 and PNPT1 regulate TRIP13 expression in CRC. Additionally, RNA sequencing of CRC cells with TRIP13 knockdown identified COL6A3, TREM2, SHC3, and KLK7 as downstream targets that may have functional relevance in TRIP13‐mediated tumor growth and metastasis. In summary, our results demonstrated that TRIP13 promotes tumor growth and metastasis regardless of p53 and MSI status, and indicated that it is a target for therapy of CRC.Abbreviations- CIN
- chromosomal instability
- CRC
- colorectal cancer
- EMT
- epithelial–mesenchymal transition
- FFPE
- formalin‐fixed, paraffin‐embedded
- LEF
- lymphoid enhancer factor
- MS
- microsatellite
- MSI
- microsatellite instable
- MSS
- microsatellite stable
- NSG
- NOD/SCID/IL2γ receptor‐null
- NT
- nontargeting
- SAC
- spindle assembly checkpoint
- TCF
- T‐cell factor
- TRIP13
- thyroid hormone receptor interactor 13
- UAB
- University of Alabama at Birmingham
|
| |
| Keywords: | colorectal cancer, EGFR, FGFR4, metastasis, TRIP13, WNT/β ‐ catenin |
|
|
